Biotech - Oncology
•302 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (302)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Biotech oncology assets in Lilly's pipeline (e.g., Jaypirca, ADCs) are central to growth.
|
$816.66B |
$863.11
+2.20%
|
|
JNJ
Johnson & Johnson
J&J's oncology pipeline (CAR-T, bispecifics, etc.) positions it as Biotech - Oncology with multiple multi‑year growth catalysts.
|
$454.86B |
$188.88
-0.09%
|
|
ABBV
AbbVie Inc.
AbbVie’s oncology efforts (Venclexta, Imbruvica, Elahere ADC) position it within Biotech - Oncology.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
AZN's oncology leadership with multiple marketed cancer therapies and a rich oncology pipeline.
|
$255.44B |
$82.39
+0.06%
|
|
MRK
Merck & Co., Inc.
Merck's pipeline and launches span multiple oncology indications, indicating a strong biotech-oncology focus.
|
$215.90B |
$85.99
-0.34%
|
|
AMGN
Amgen Inc.
IMDELLTRA and other assets position Amgen as a major Biotech - Oncology player.
|
$160.47B |
$298.45
+2.21%
|
|
GILD
Gilead Sciences, Inc.
Oncology focus across ADCs, CAR-T, and associated pipelines supports Biotech - Oncology.
|
$149.01B |
$119.77
+1.12%
|
|
PFE
Pfizer Inc.
Biotech - Oncology captures Pfizer's focus on cancer therapies and ADC-driven oncology strategies.
|
$140.14B |
$24.66
+1.50%
|
|
BMY
Bristol-Myers Squibb Company
BMY is pivoting toward an oncology-focused Growth Portfolio, making Biotech - Oncology a primary investable theme.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Pipeline includes oncology and hematology assets (Libtayo, bispecifics) driving an oncology focus.
|
$69.08B |
$651.52
-0.39%
|
|
ZTS
Zoetis Inc.
Zoetis' pipeline includes oncology assets, aligning with Biotech - Oncology as a potential investable theme.
|
$64.15B |
$144.07
+0.33%
|
|
TAK
Takeda Pharmaceutical Company Limited
Oncology is a core focus with late-stage assets and a significant pipeline potential (e.g., FRUZAQLA in colorectal cancer).
|
$42.61B |
$13.44
+1.59%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$33.55B |
$310.56
+0.76%
|
|
BNTX
BioNTech SE
The company is pivoting toward oncology with immunotherapies, making Biotech - Oncology a core product/business focus.
|
$24.91B |
$103.92
-0.72%
|
|
UTHR
United Therapeutics Corporation
Unituxin (dinutuximab) is a cancer therapy marketed by UTHR, placing the company in Biotech - Oncology.
|
$20.15B |
$445.96
-1.67%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$18.93B |
$28.60
-0.24%
|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$18.25B |
$93.49
+0.97%
|
|
SMMT
Summit Therapeutics Inc.
Summit is transforming into an oncology-focused biotech centered on ivonescimab.
|
$14.05B |
$18.91
+1.45%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$10.96B |
$58.81
-0.10%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$10.55B |
$38.67
-0.69%
|
|
MRNA
Moderna, Inc.
Oncology therapeutics portfolio, including personalized neoantigen vaccines, expands Moderna's pipeline beyond vaccines into cancer therapies.
|
$10.50B |
$27.16
-3.50%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's oncology assets (e.g., Dordaviprone and Zanidatamab) place the company in Biotech - Oncology.
|
$8.48B |
$137.62
+0.97%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
CORT
Corcept Therapeutics Incorporated
ROSELLA trial demonstrated relacorilant in platinum-resistant ovarian cancer, aligning with 'Biotech - Oncology' as a major oncology platform.
|
$7.79B |
$73.45
+1.65%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.16B |
$99.28
+1.13%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$6.57B |
$94.86
-0.21%
|
|
LEGN
Legend Biotech Corporation
Legend Biotech operates as a biotechnology company focused on oncology, reflecting its core emphasis on cancer therapies.
|
$5.94B |
$32.40
+0.47%
|
|
KRYS
Krystal Biotech, Inc.
KB707 and the oncology pipeline indicate Krystal Biotech's involvement in cancer immunotherapy in solid tumors.
|
$5.71B |
$196.63
+3.99%
|
|
CRSP
CRISPR Therapeutics AG
Oncology/hematologic malignancy indications are targeted by the pipeline (CAR-T programs).
|
$5.53B |
$64.02
+4.78%
|
|
ACLX
Arcellx, Inc.
Company focuses on oncology therapeutics via engineered cell therapies, aligning with cancer treatment.
|
$4.97B |
$90.33
+3.23%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Narrow oncology-focused NDCs and SST2-targeted tumor payloads indicate cancer therapeutics development.
|
$4.08B |
$43.50
+0.51%
|
|
LNTH
Lantheus Holdings, Inc.
Oncology-focused radiopharmaceutical assets and GRPR-targeted theranostics in the pipeline indicate an oncology biotech exposure.
|
$3.99B |
$57.70
+3.97%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
CNTA
Centessa Pharmaceuticals plc
Asset-centric immuno-oncology and oncology-focused platform positioning place Centessa in 'Biotech - Oncology'.
|
$3.33B |
$24.89
+2.32%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$3.30B |
$43.28
+1.91%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$2.92B |
$77.24
-2.18%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.83B |
$26.12
+2.37%
|
|
SRRK
Scholar Rock Holding Corporation
SRK-181 and oncology-focused programs place Scholar Rock in the cancer therapeutics space.
|
$2.81B |
$29.68
+1.04%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$2.79B |
$31.87
+0.85%
|
|
ADPT
Adaptive Biotechnologies Corporation
Genentech oncology collaboration supports Adaptive's oncology immunotherapy focus.
|
$2.64B |
$17.36
+2.69%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.63B |
$33.67
+2.92%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Pipeline includes precision oncology programs, indicating oncology-focused biotech activity.
|
$2.24B |
$5.50
-2.65%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$2.12B |
$2.39
+1.27%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.10B |
$19.72
-2.33%
|
|
GLPG
Galapagos N.V.
Strategic focus on oncology cell therapies and cancer indications.
|
$2.09B |
$31.78
+1.40%
|
|
COGT
Cogent Biosciences, Inc.
Cogent operates in oncology, developing targeted cancer therapies, aligning with Biotech - Oncology.
|
$1.86B |
$16.30
+0.56%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$1.78B |
$5.21
+1.26%
|
|
BHVN
Biohaven Ltd.
Oncology represents a major focus with ADCs and tumor-targeting approaches in Biohaven's pipeline.
|
$1.76B |
$17.20
-1.06%
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$1.70B |
$28.70
+0.67%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.66B |
$33.00
+2.52%
|
|
ABCL
AbCellera Biologics Inc.
Biotech oncology focus via antibody/immunotherapy programs within the pipeline.
|
$1.66B |
$5.54
+3.36%
|
|
SDGR
Schrödinger, Inc.
The company operates a proprietary drug discovery pipeline with programs in oncology, aligning with Biotech - Oncology.
|
$1.54B |
$21.02
+2.74%
|
|
IMNM
Immunome, Inc.
Immunome is a clinical-stage oncology-focused biotech company with ADC and RLT assets.
|
$1.40B |
$16.08
+0.63%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$1.33B |
$19.07
-0.26%
|
|
RLAY
Relay Therapeutics, Inc.
Directly develops oncology therapies (lead asset RLY-2608) and precision medicine leveraging its platform.
|
$1.22B |
$7.13
-2.86%
|
|
PGEN
Precigen, Inc.
PRGN-2009 and other oncology programs position the company in Oncology biotech.
|
$1.22B |
$4.14
+2.35%
|
|
CVAC
CureVac N.V.
CureVac's core focus is oncology immunotherapies and cancer vaccines built on its mRNA platform (Biotech - Oncology).
|
$1.20B |
$5.34
-0.37%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.18B |
$81.68
+4.04%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.18B |
$13.71
+2.35%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$1.15B |
$23.45
-2.17%
|
|
SANA
Sana Biotechnology, Inc.
Pipeline includes CD19/CD22 CAR T therapies for B-cell malignancies and autoimmune targets, aligning with oncology.
|
$1.12B |
$4.94
+0.82%
|
|
OPK
OPKO Health, Inc.
Biotech - Oncology reflects ModeX's early-stage antibody oncology programs.
|
$1.08B |
$1.34
-7.88%
|
|
IMTX
Immatics N.V.
Primary focus on oncology and cancer immunotherapy.
|
$1.05B |
$10.19
-2.21%
|
|
XNCR
Xencor, Inc.
Oncology-focused biotech developing antibody-based cancer therapies.
|
$1.05B |
$14.70
+4.00%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$989.80M |
$20.89
+13.29%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$989.25M |
$12.95
+1.33%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$943.82M |
$20.45
+3.02%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$935.52M |
$13.17
-1.27%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$889.12M |
$10.26
-1.72%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$886.21M |
$16.24
-1.34%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$879.08M |
$8.11
+1.69%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA is a oncology-focused biotech developing FGFR inhibitors for cancer indications.
|
$842.34M |
$15.83
+0.96%
|
|
VIR
Vir Biotechnology, Inc.
Vir is expanding a targeted oncology portfolio around masked T-cell engagers, placing it in Biotech - Oncology.
|
$823.90M |
$5.95
+0.34%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$802.52M |
$1.26
+1.61%
|
|
RZLT
Rezolute, Inc.
The tumor HI indication involves cancer-related hypoglycemia; Rezolute's asset has implications in oncology, thus Biotech - Oncology applies.
|
$797.04M |
$9.32
-5.04%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
Pipeline targets oncology indications (e.g., MRT-2359 for CRPC), making Biotech - Oncology a core tag.
|
$790.40M |
$12.86
-1.19%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Company operates as Biotech - Oncology focusing on cancer therapies (pLGG).
|
$754.14M |
$7.43
+5.54%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$750.05M |
$9.73
-5.07%
|
|
MYGN
Myriad Genetics, Inc.
Biotech - Oncology: company focused on cancer diagnostics across oncology segment.
|
$741.11M |
$8.04
+1.07%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$740.13M |
$10.14
+2.11%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$736.24M |
$25.52
+5.41%
|
|
TERN
Terns Pharmaceuticals, Inc.
TERNs Pharmaceuticals is a biotech company actively developing oncology therapies, including a BCR-ABL targeted inhibitor for CML (TERN-701).
|
$721.41M |
$8.25
+1.10%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$685.56M |
$2.42
-1.63%
|
|
FLGT
Fulgent Genetics, Inc.
Biotech - Oncology focus.
|
$683.46M |
$22.44
-0.62%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics develops oncology therapeutics, with Amtagvi lifileucel representing an autologous TIL cell therapy for solid tumors.
|
$657.85M |
$1.96
+0.51%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$640.80M |
$18.73
+1.38%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$620.00M |
$8.04
+3.54%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Olema is a biotechnology company focused on oncology therapies, including palazestrant in ER+ breast cancer.
|
$613.74M |
$8.97
+2.16%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$564.41M |
$31.58
-0.13%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$559.30M |
$8.05
-8.05%
|
|
ABSI
Absci Corporation
Pipeline includes oncology antibody programs, fitting Biotech - Oncology.
|
$545.95M |
$4.29
+4.77%
|
|
IMAB
I-Mab
I-Mab operates as a biotechnology company focused on oncology, with a pipeline of differentiated immuno-oncology therapies for cancer.
|
$533.68M |
$4.64
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$526.89M |
$88.06
+2.79%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$519.27M |
$9.45
+2.33%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$517.18M |
$3.73
+0.40%
|
|
CGEM
Cullinan Therapeutics, Inc.
Company's focus on oncology and immunology therapeutics aligns with Biotech - Oncology.
|
$511.07M |
$8.66
+14.62%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$499.56M |
$30.17
+1.58%
|
|
PRTC
PureTech Health plc
Lead asset LYT-200 in Gallop Oncology positions PureTech in oncology-focused biotech.
|
$458.47M |
$17.68
+3.97%
|
|
ADCT
ADC Therapeutics S.A.
The company operates in oncology with ADC-based therapeutics, categorized under Biotech - Oncology.
|
$442.34M |
$4.45
-3.89%
|
|
OMER
Omeros Corporation
OncotoX platform targets oncology indications, a major pipeline focus for the company.
|
$429.48M |
$7.32
-2.66%
|
Showing page 1 of 4 (302 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
